Recruiting
Phase 1

CBD & THC

Sponsor:

UCLA

Code:

NCT06859710

Conditions

Abuse, Drug

Pain

Eligibility Criteria

Sex: All

Age: 21 - 55

Healthy Volunteers: Accepted

Interventions

Placebo

THC

CBD 20 mg

CBD 40 mg

CBD 80 mg

Study Details

Brief summary:

The purpose of this research is to assess the impact of CBD on the effects of THC.

Conditions

Abuse, Drug

Pain

Study ID

NCT06859710

Start date

Nov 5, 2025

Status verified date

Sep, 2025

Completion date

Sep 1, 2028

Anticipated

Primary completion date

Sep 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21 - 55

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Male or non-pregnant and non-lactating females aged 21-55 years
  • Report cannabis use 1-7 days per week over the month prior to screening
  • Not currently seeking treatment for their cannabis use
  • History of inhaled cannabis use
  • Have a Body Mass Index from 18.5 - 34 kg/m2
  • Able to perform all study procedures
  • Must be using a contraceptive (hormonal or barrier methods)

Exclusion Criteria:

  • Meeting DSM-V criteria for severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, mild or moderate CUD
  • Evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and PI) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent.
  • Report using other illicit drugs in the prior 4 weeks
  • Current pain
  • Pregnancy
  • Currently enrolled in another research protocol
  • Not using a contraceptive method (hormonal or barrier methods)
  • Insensitivity to the cold water stimulus of the Cold Pressor Test
  • Any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history.
  • Not able to speak and read English

Study Design

Enrollment

30 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

placebo comparator: Placebo

0 mg THC, 0 mg CBD

active comparator: THC

20 mg THC, 0 mg CBD

active comparator: CBD 20

0 mg THC, 20 mg CBD

active comparator: CBD 40

0 mg THC, 40 mg CBD

active comparator: CBD 80

0 mg THC, 80 mg CBD

active comparator: THC with CBD 20

20 mg THC, 20 mg CBD

active comparator: THC with CBD 40

20 mg THC, 40 mg CBD

active comparator: THC with CBD 80

20 mg THC, 80 mg CBD

Interventions

Placebo

Vaporized Placebo

THC

Vaporized THC (20 mg)

CBD 20 mg

Vaporized CBD (20 mg)

CBD 40 mg

Vaporized CBD (40 mg)

CBD 80 mg

Vaporized CBD (80 mg)

Primary outcome measure

  • Subject-rated drug effects of abuse liability [ Time Frame: 3 hours ]
  • Analgesia as measured using the Cold Pressor Test [ Time Frame: 3 hours ]
  • Behavioral task performance as assessed by the DRUID App Score [ Time Frame: 3 hours ]
  • Pharmacokinetics of THC [ Time Frame: 3 hours ]

Central Contacts and Locations

Central contacts

Ziva Cooper, PhD

310-206-9942zcooper@mednet.ucla.edu

Vincent Acebo

310-983-3417vacebo@mednet.ucla.edu

Locations

UCLA Center for Cannabis and Cannabinoids

Recruiting

Los Angeles, California, United States, 90095

Contacts

Ziva D Cooper, PhD

(310) 794 -1497cannabislab@mednet.ucla.edu

Vince Acebo

vacebo@mednet.ucla.edu

More Information

Sponsor

University of California, Los Angeles

Last update posted

Dec 17, 2025

Last verified

Sep, 2025

Keywords

  • Cannabis
  • THC
  • CBD

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of California, Los Angeles on 2025-12-17.